Strontium ranelate's effect on bone of rat with established

GONZALES CHAVES M; MAROTTE C; PELLEGRINI G; ORZUZA R; FRIEDMAN S; PARISI M; MANDALUNIS P; ZENI SN

Rosario, Argentina

Congreso; XXIV Reunión de la Asociación Argentina de Osteología y Metabolismo Mineral; 2007

AAOOM

Strontium (Sr) and calcium (Ca) are chemically related alkaline earth elements. In the short term, Sr atoms are adsorbed onto the hydroxyapatite crystals´ surface. Sr as Sr ranelate (SrRa) is used to treat osteoporosis. In OVX rats, 3 months after surgery, SrRa reduced bone remodeling and increased bone mineral content (BMC), but this study was published only as an abstract (Bone 13 A1, 1992). The objective was to determine the effect of SrRa in BMC, BMD and bone volume in OVX rats with established osteopenia. 10 SHAM and 40 OVX osteopenic rats were studied. 20 OVX were treated with vehicle (Vh) and 20 with SrRa (900 mg/kg/ day) for 45 days. At 0, 60 and 105 days, total skeleton (te) BMD and BMC were assessed by DXA. BMC was expressed as BMC/BW and changes between the end of the experience (105 days) and onset of treatment (60 days) [teBMC/BW (105−60)] was calculated. At the day 105, rats were sacrificed and total bone volume in tibia was assessed by histology. sacrificed and total bone volume in tibia was assessed by histology. sacrificed and total bone volume in tibia was assessed by histology. sacrificed and total bone volume in tibia was assessed by histology. −60)] was calculated. At the day 105, rats were sacrificed and total bone volume in tibia was assessed by histology. Results: (different letter indicates a p b0.001): SrRa treatment did not affect BMD of total skeleton and the studied subareas. The corrected teBMC (−10%) of OVX+SrRa was higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and treatment did not affect BMD of total skeleton and the studied subareas. The corrected teBMC (−10%) of OVX+SrRa was higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and treatment did not affect BMD of total skeleton and the studied subareas. The corrected teBMC (−10%) of OVX+SrRa was higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and treatment did not affect BMD of total skeleton and the studied subareas. The corrected teBMC (−10%) of OVX+SrRa was higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and (different letter indicates a p b0.001): SrRa treatment did not affect BMD of total skeleton and the studied subareas. The corrected teBMC (−10%) of OVX+SrRa was higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and −10%) of OVX+SrRa was higher than that of SHAM and OVX+Vh groups (8.29±1.32b vs. 6.68 ±0.55a and 7.09±1.3a, respectively). The teBMC/BW (105−60) was also higher (1.06±1.44b vs. −1.72±1.08a and−60) was also higher (1.06±1.44b vs. −1.72±1.08a and −1.24±3a, respectively). The bone volume of OVX+SrRa was 50% higher than in OVX+Vh (5.0±3.2b vs. 2.6± 50% higher than in OVX+Vh (5.0±3.2b vs. 2.6± 50% higher than in OVX+Vh (5.0±3.2b vs. 2.6± 50% higher than in OVX+Vh (5.0±3.2b vs. 2.6± 1.24±3a, respectively). The bone volume of OVX+SrRa was 50% higher than in OVX+Vh (5.0±3.2b vs. 2.6± Conclusions: Under our experimental conditions, Sr may be incorporated into the formed bone, with lower positive effect in formation of new bone. Grant from CONICET PIP 6483. incorporated into the formed bone, with lower positive effect in formation of new bone. Grant from CONICET PIP 6483. incorporated into the formed bone, with lower positive effect in formation of new bone. Grant from CONICET PIP 6483. incorporated into the formed bone, with lower positive effect in formation of new bone. Grant from CONICET PIP 6483. Under our experimental conditions, Sr may be incorporated into the formed bone, with lower positive effect in formation of new bone. Grant from CONICET PIP 6483.